• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

碳水化合物抗原 125 与射血分数保留心力衰竭患者心力衰竭再入院风险。

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction.

机构信息

Cardiology Department, Hospital Clínico Universitario de Valencia, Universitat de Valencia, INCLIVA, Avda. Blasco Ibáñez 17, 46010, Valencia, Spain.

CIBER Cardiovascular, Madrid, Spain.

出版信息

Sci Rep. 2022 Jan 25;12(1):1344. doi: 10.1038/s41598-022-05328-2.

DOI:10.1038/s41598-022-05328-2
PMID:35079082
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8789924/
Abstract

We aimed to assess the association between CA125 and the long-term risk of total acute heart failure (AHF) admissions in patients with an index hospitalization with AHF and preserved ejection fraction (HFpEF). We prospectively included 2369 patients between 2008 and 2019 in three centers. CA125 and NT-proBNP were measured during early hospitalization and evaluated as continuous and categorized in quartiles (Q). Negative binomial regressions were used to assess the association with the risk of recurrent AHF admission. The mean age of the sample patients was 76.7 ± 9.5 years and 1443 (60.9%) were women. Median values of CA125 and NT-proBNP were 38.3 (19.0-90.0) U/mL, and 2924 (1590-5447) pg/mL, respectively. During a median follow-up of 2.2 (0.8-4.6) years, 1200 (50.6%) patients died, and 2084 AHF admissions occurred in 1029 (43.4%) patients. After a multivariate adjustment, CA125, but not NT-proBNP, was positively and non-linearly associated with the risk of cumulative AHF-readmission (p < 0.001). Compared to Q1, patients belonging to Q2, Q3, and Q4 showed a stepwise risk increase (IRR = 1.29, 95% CI 1.08-1.55, p = 0.006; IRR = 1.35, 95% CI 1.12-1.63, p = 0.002; and IRR = 1.62, 95% CI 01.34-1.96, p < 0.001, respectively). In conclusion, CA125 predicted the risk of long-term AHF-readmission burden in patients with HFpEF and a recent admission for AHF.

摘要

我们旨在评估 CA125 与因射血分数保留的心力衰竭(HFpEF)而住院的患者的长期总急性心力衰竭(AHF)入院风险之间的关系。我们前瞻性地纳入了 2008 年至 2019 年三个中心的 2369 名患者。在住院早期测量 CA125 和 NT-proBNP,并将其评估为连续和四分之一分位数(Q)。使用负二项回归来评估与复发性 AHF 入院风险的关系。样本患者的平均年龄为 76.7±9.5 岁,1443 名(60.9%)为女性。CA125 和 NT-proBNP 的中位数分别为 38.3(19.0-90.0)U/mL 和 2924(1590-5447)pg/mL。中位随访 2.2(0.8-4.6)年后,1200 名(50.6%)患者死亡,1029 名(43.4%)患者中有 2084 名发生 AHF 入院。在多变量调整后,CA125 但不是 NT-proBNP 与累积 AHF 再入院风险呈正相关且呈非线性相关(p<0.001)。与 Q1 相比,属于 Q2、Q3 和 Q4 的患者的风险呈逐步增加(IRR=1.29,95%CI 1.08-1.55,p=0.006;IRR=1.35,95%CI 1.12-1.63,p=0.002;IRR=1.62,95%CI 01.34-1.96,p<0.001)。总之,CA125 预测了 HFpEF 患者近期因 AHF 住院后长期 AHF 再入院负担的风险。

相似文献

1
Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction.碳水化合物抗原 125 与射血分数保留心力衰竭患者心力衰竭再入院风险。
Sci Rep. 2022 Jan 25;12(1):1344. doi: 10.1038/s41598-022-05328-2.
2
CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation.在伴有严重三尖瓣反流的急性心力衰竭中,CA125的表现优于N末端B型利钠肽原。
Int J Cardiol. 2020 Jun 1;308:54-59. doi: 10.1016/j.ijcard.2020.03.027. Epub 2020 Mar 21.
3
[Carbohydrate antigen 125 serial measurements after an admission for acute heart failure and risk of early readmission].[急性心力衰竭入院后糖类抗原125的连续测量及早期再入院风险]
Med Clin (Barc). 2012 Nov 3;139(11):479-86. doi: 10.1016/j.medcli.2011.05.029. Epub 2011 Nov 16.
4
Prognostic value of carbohydrate antigen 125 combined with N-terminal pro B-type natriuretic peptide in patients with acute heart failure.糖链抗原 125 联合氨基末端脑利钠肽前体对急性心力衰竭患者预后的评估价值。
Acta Cardiol. 2021 Feb;76(1):87-92. doi: 10.1080/00015385.2020.1769347. Epub 2020 Jun 10.
5
CA125 but not NT-proBNP predicts the presence of a congestive intrarenal venous flow in patients with acute heart failure.CA125 而非 NT-proBNP 可预测急性心力衰竭患者存在充血性肾内静脉血流。
Eur Heart J Acute Cardiovasc Care. 2021 Jun 30;10(5):475-483. doi: 10.1093/ehjacc/zuab022.
6
Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure.抗原碳水化合物 125 在急性心力衰竭中计划最佳住院时间的临床实用性。
Eur J Intern Med. 2021 Oct;92:94-99. doi: 10.1016/j.ejim.2021.05.037. Epub 2021 Jun 12.
7
Long-term serial kinetics of N-terminal pro B-type natriuretic peptide and carbohydrate antigen 125 for mortality risk prediction following acute heart failure.急性心力衰竭后死亡风险预测的 N 末端 B 型利钠肽原和糖类抗原 125 的长期序列动力学。
Eur Heart J Acute Cardiovasc Care. 2017 Dec;6(8):685-696. doi: 10.1177/2048872616649757. Epub 2016 May 19.
8
Comparison between CA125 and NT-proBNP for evaluating congestion in acute heart failure.CA125 与 NT-proBNP 用于评估急性心力衰竭患者充血的比较。
Med Clin (Barc). 2021 Jun 25;156(12):589-594. doi: 10.1016/j.medcli.2020.05.063. Epub 2020 Sep 18.
9
Carbohydrate antigen 125 (CA125) as a prognostic marker in the elderly with acute heart failure and preserved ejection fraction.糖链抗原 125(CA125)作为射血分数保留的老年急性心力衰竭患者的预后标志物。
Med Clin (Barc). 2022 Aug 26;159(4):164-170. doi: 10.1016/j.medcli.2021.09.032. Epub 2021 Dec 8.
10
Prognostic value of NT-proBNP and CA125 across glomerular filtration rate categories in acute heart failure.急性心力衰竭中不同肾小球滤过率类别下NT-proBNP和CA125的预后价值
Eur J Intern Med. 2022 Jan;95:67-73. doi: 10.1016/j.ejim.2021.08.024. Epub 2021 Sep 8.

引用本文的文献

1
Paradox of Low CA-125 in Patients with Decompensated Congestive Heart Failure.失代偿性充血性心力衰竭患者CA-125水平降低的矛盾现象。
Biomedicines. 2025 Jul 9;13(7):1679. doi: 10.3390/biomedicines13071679.
2
CA125 as a Potential Biomarker in Non-Malignant Serous Effusions: Diagnostic and Prognostic Considerations.CA125作为非恶性浆液性积液中的潜在生物标志物:诊断和预后考量
J Clin Med. 2025 Jun 11;14(12):4152. doi: 10.3390/jcm14124152.
3
Carbohydrate antigen 125 determined on arrival at the emergency department correlates with severity of decompensation and adverse outcomes in patients with acute heart failure.

本文引用的文献

1
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review.抗原碳水化合物 125 作为心力衰竭的生物标志物:叙述性综述。
Eur J Heart Fail. 2021 Sep;23(9):1445-1457. doi: 10.1002/ejhf.2295. Epub 2021 Jul 20.
2
Clinical utility of antigen carbohydrate 125 for planning the optimal length of stay in acute heart failure.抗原碳水化合物 125 在急性心力衰竭中计划最佳住院时间的临床实用性。
Eur J Intern Med. 2021 Oct;92:94-99. doi: 10.1016/j.ejim.2021.05.037. Epub 2021 Jun 12.
3
The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations.
急诊科就诊时测定的糖类抗原125与急性心力衰竭患者失代偿的严重程度及不良预后相关。
Intern Emerg Med. 2025 May 5. doi: 10.1007/s11739-025-03932-4.
4
Serum CA125: a prognostic biomarker for mortality in chronic heart failure.血清CA125:慢性心力衰竭死亡率的预后生物标志物。
BMC Cardiovasc Disord. 2025 Mar 27;25(1):227. doi: 10.1186/s12872-025-04685-w.
5
Biomarkers for Congestion in Heart Failure: State-of-the-art and Future Directions.心力衰竭中充血的生物标志物:现状与未来方向。
Card Fail Rev. 2025 Jan 27;11:e01. doi: 10.15420/cfr.2024.32. eCollection 2025.
6
Biomarkers in Heart Failure with Preserved Ejection Fraction: A Perpetually Evolving Frontier.射血分数保留的心力衰竭中的生物标志物:一个不断发展的前沿领域。
J Clin Med. 2024 Aug 7;13(16):4627. doi: 10.3390/jcm13164627.
7
CA125 outperforms NT-proBNP in the prediction of maximum aerobic capacity in heart failure with preserved ejection fraction and kidney dysfunction.在射血分数保留的心力衰竭合并肾功能不全患者中,CA125在预测最大有氧能力方面优于NT-proBNP。
Clin Kidney J. 2024 Jul 2;17(8):sfae199. doi: 10.1093/ckj/sfae199. eCollection 2024 Aug.
8
Carbohydrate Antigen 125 (CA 125): A Novel Biomarker in Acute Heart Failure.糖类抗原125(CA 125):急性心力衰竭中的一种新型生物标志物。
Diagnostics (Basel). 2024 Apr 10;14(8):795. doi: 10.3390/diagnostics14080795.
9
Carbohydrate antigen 125: a useful marker of congestion, fibrosis, and prognosis in heart failure with preserved ejection fraction.糖类抗原 125:心力衰竭伴射血分数保留的标志物,可用于评估充血、纤维化和预后。
ESC Heart Fail. 2024 Jun;11(3):1493-1505. doi: 10.1002/ehf2.14699. Epub 2024 Feb 9.
10
Diagnosis of heart failure with preserved ejection fraction: a systematic narrative review of the evidence.射血分数保留的心力衰竭的诊断:证据的系统叙述性综述。
Heart Fail Rev. 2024 Jan;29(1):179-189. doi: 10.1007/s10741-023-10360-z. Epub 2023 Oct 20.
性别和体重指数对可溶性脑啡肽酶与心力衰竭住院风险之间关联的影响。
Sci Rep. 2021 Mar 15;11(1):5940. doi: 10.1038/s41598-021-85490-1.
4
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.铁羧基麦芽糖治疗急性心力衰竭出院后缺铁:一项多中心、双盲、随机、对照试验。
Lancet. 2020 Dec 12;396(10266):1895-1904. doi: 10.1016/S0140-6736(20)32339-4. Epub 2020 Nov 13.
5
CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation.在伴有严重三尖瓣反流的急性心力衰竭中,CA125的表现优于N末端B型利钠肽原。
Int J Cardiol. 2020 Jun 1;308:54-59. doi: 10.1016/j.ijcard.2020.03.027. Epub 2020 Mar 21.
6
Clinical Role of CA125 in Worsening Heart Failure: A BIOSTAT-CHF Study Subanalysis.CA125 在心力衰竭恶化中的临床作用:BIOSTAT-CHF 研究的亚组分析。
JACC Heart Fail. 2020 May;8(5):386-397. doi: 10.1016/j.jchf.2019.12.005. Epub 2020 Mar 11.
7
Factors associated with plasma antigen carbohydrate 125 and amino-terminal pro-B-type natriuretic peptide concentrations in acute heart failure.与急性心力衰竭患者血浆抗原糖 125 和氨基末端 pro-B 型利钠肽浓度相关的因素。
Eur Heart J Acute Cardiovasc Care. 2020 Aug;9(5):437-447. doi: 10.1177/2048872620908033. Epub 2020 Mar 4.
8
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的应用。
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
9
CA125-Guided Diuretic Treatment Versus Usual Care in Patients With Acute Heart Failure and Renal Dysfunction.CA125 指导的利尿剂治疗与急性心力衰竭伴肾功能障碍患者的常规治疗比较。
Am J Med. 2020 Mar;133(3):370-380.e4. doi: 10.1016/j.amjmed.2019.07.041. Epub 2019 Aug 15.
10
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.欧洲心脏病学会心力衰竭协会关于利钠肽浓度检测的临床应用实践指南
Eur J Heart Fail. 2019 Jun;21(6):715-731. doi: 10.1002/ejhf.1494.